GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Meropenem

Read renal action and limits

Merrem / Merrem IV

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (6)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Merrem IV - product and source limitations

The FDA label has insufficient information for hemodialysis or peritoneal dialysis. Separate institutional regimens carry their own assumptions.

Before applying: Verify the current prescribing information for this presentation.

Also check: Merrem IV - product and source limitations

Professional source

Merrem IV - UCSF Infectious Diseases Management Program

Choose a product and source Product label GlobalRPh RX passage All evidence
Product / population
UCSF adult IV meropenem, standard indications only.
Renal measure
Intermittent HD versus CVVHD.
Source revision
Online guidance checked 2026-11-07; section revision not established.
Retrieved
2026-11-07 (not the revision date)
Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.

Hemodialysis, standard dosing row

For a standard infection, the institution lists 500 mg IV once, then every evening on intermittent HD. Its CVVHD standard is 1 g IV every 8 hours. Meningitis and cystic fibrosis have separate schedules. Confirm flow, indication and infusion duration before using this institutional guidance.

Source revision: Online guidance checked 2026-11-07; section revision not established. | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://idmp.ucsf.edu/content/meropenem

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Merrem IV - labeled renal guidance

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Meropenem (Merrem IV), adult IV use for labeled infections

Renal method: Cockcroft-Gault creatinine clearance, mL/min
Retrieved: 2026-11-07

GlobalRPh RX List

Merrem IV - selected RX renal passage

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Meropenem (Merrem IV), adult IV use for labeled infections

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Professional guidance

Merrem IV - UCSF Infectious Diseases Management Program

Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.

UCSF adult IV meropenem, standard indications only.

Renal method: Intermittent HD versus CVVHD.
Retrieved: 2026-11-07

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Merrem IV - product and source limitations

The FDA label has insufficient information for hemodialysis or peritoneal dialysis. Separate institutional regimens carry their own assumptions.

How to use this: Verify the current prescribing information for this presentation.

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The non-label dialysis regimens are separate GlobalRPh reference material, not manufacturer instructions. No renal-adjusted meningitis regimen is inferred.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/meropenem/

Usual Dosing (Adults)

Usual: 1 g IV every 8 hours. Complicated skin/skin-structure infection: 500 mg every 8 hours. Intra-abdominal infection: 1 g every 8 hours. Meningitis: 2 g every 8 hours.

GRPH-meropenem-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

CrCl above 50 mL/min: no change. CrCl 26-50: usual 1 g every 12 hours, or 500 mg every 12 hours for UTI/skin infection. CrCl 10-25: usual 500 mg every 12 hours, or 250 mg every 12 hours for UTI/skin infection. CrCl below 10: usual 500 mg every 24 hours, or 250 mg every 24 hours for UTI/skin infection.

GRPH-meropenem-02 · Source section: Renal DosingRenal section finder

Hemodialysis

The source states that the package insert has inadequate information for hemodialysis and no peritoneal-dialysis experience. It then gives separate other-reference regimens: hemodialysis, 500 mg every 24 hours plus 500 mg after dialysis; peritoneal dialysis, 500 mg every 24 hours.

GRPH-meropenem-03 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Merrem IV - labeled renal guidance

Open original reference

Open / share this exact local source

FDA / product prescribing information · Meropenem (Merrem IV), adult IV use for labeled infections

Renal method: Cockcroft-Gault creatinine clearance, mL/min
Source date: Prescribing information revised 12/2024
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 2, adult patients with renal impairment

Limits that apply to these rows

The FDA label has insufficient information for hemodialysis or peritoneal dialysis. Separate institutional regimens carry their own assumptions.

Adult renal dosing in this source
CrCl (mL/min)Fraction of usual indication doseInterval
>50FullEvery 8 hours
26-50FullEvery 12 hours
10-25HalfEvery 12 hours
<10HalfEvery 24 hours
Read the retained text before reformatting

Start with the usual dose for the infection. CrCl >50: usual dose every 8 hours. At 26-50: usual dose every 12 hours. At 10-25: half the usual dose every 12 hours. Below 10: half the usual dose every 24 hours. The FDA label has insufficient information for hemodialysis or peritoneal dialysis. Separate institutional regimens carry their own assumptions.

RDM73-merrem-iv-official-1 · Source locator: Renal guidance: 2, adult patients with renal impairment

Source identity and provenance
Source family
product_label
Source
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/050706s044lbl.pdf
Retrieved
2026-11-07
Renal-function method
Cockcroft-Gault creatinine clearance, mL/min
Source date/version
Prescribing information revised 12/2024
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
c64aa624e647ecde699ed7878ffa82018f66a0266bd005f0334828dac0d90c9f
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Merrem IV - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Meropenem (Merrem IV), adult IV use for labeled infections

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror uses indication-specific starting doses, then changes dose and/or interval across CrCl bands.

RDM73-merrem-iv-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/merrem-iv-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
bfc18a65bea97de098f957a388aa9967078d27fe64939af2eea7a69174526011
Separate professional-source layer

University and professional protocols

Professional

UCSF - meropenem: indication-specific renal doses

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

IV short-infusion regimens for renal bands >50 / 26-50 / 10-25 / <10 mL/min:

  • Standard: 1 g every 8 hours / 1 g every 12 hours / 500 mg every 12 hours / 500 mg daily.
  • Meningitis or cystic fibrosis: 2 g every 8 hours / 2 g every 12 hours / 1 g every 12 hours / 1 g daily.

IHD: standard 500 mg initially, then every evening; meningitis/cystic fibrosis 1 g initially, then every evening.

CVVHD: standard 1 g every 8 hours; meningitis/cystic fibrosis 2 g every 12 hours. Discuss flow exceeding 2 L/hour with ID pharmacy.

Selected extended infusion uses a 1 g loading dose over 30 minutes, with maintenance beginning 4 hours later. At renal function >50 / 26-50, standard maintenance is 1 g over 3 hours every 8 / 12 hours; meningitis/cystic fibrosis maintenance is 2 g at those intervals. Below 26, use short infusion. Meningitis extended-infusion evidence is limited.

RDM30-002-meropenem-1 · Source locator: UCSF - meropenem: indication-specific renal doses; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/meropenem
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
58f2512194729f4eb0d26cdadc465a2322524b4b9ed22f538e44c5cb87ebd2fc
Professional

Nebraska Medicine - meropenem by CVVHD flow

Open original reference

Open / share this exact local source

University of Nebraska Medical Center / Nebraska Medicine · Adults; IV meropenem, source PDF page 7.

Renal method: CVVHD dialysate flow, with indication/MIC stratification.
Source date: 2023 CRRT/PIRRT reference.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Standard CVVHD treatment: 1 g IV load then 500 mg every 6 hours at dialysate flow 1-4 L/hour. For meningitis, cystic fibrosis or MIC 4, the guide uses 2 g loading, then 2 g every 12 hours at 1 L/hour or every 8 hours at 2-4 L/hour. Do not use the anephric non-CRRT column while clearance is being provided by CVVHD.

RDM30-063-meropenem-1 · Source locator: Nebraska Medicine - meropenem by CVVHD flow; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://www.unmc.edu/intmed/_documents/id/asp/final_crrt_pirrt_abxrecommendations_2023.pdf
Retrieved
2026-09-05
Renal-function method
CVVHD dialysate flow, with indication/MIC stratification.
Source date/version
2023 CRRT/PIRRT reference.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
e0d2da552e822d24394a878f7be4e5c1f934943b59462ace94e83390647e3302
Professional

Merrem IV - UCSF Infectious Diseases Management Program

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · UCSF adult IV meropenem, standard indications only.

Renal method: Intermittent HD versus CVVHD.
Source date: Online guidance checked 2026-11-07; section revision not established.
Retrieved: 2026-11-07

Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.

Selected renal passages reviewed; independent clinician adjudication pending.

Hemodialysis, standard dosing row

For a standard infection, the institution lists 500 mg IV once, then every evening on intermittent HD. Its CVVHD standard is 1 g IV every 8 hours. Meningitis and cystic fibrosis have separate schedules. Confirm flow, indication and infusion duration before using this institutional guidance.

RDM73-merrem-iv-professional-1 · Source locator: Hemodialysis, standard dosing row

Source identity and provenance
Source family
professional_guideline
Source
https://idmp.ucsf.edu/content/meropenem
Retrieved
2026-11-07
Renal-function method
Intermittent HD versus CVVHD.
Source date/version
Online guidance checked 2026-11-07; section revision not established.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
6251e266b65434a37bad8e532aaec5cb7a5974fc1a6fae2745f8fa750ce9fc96

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 3 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/meropenem/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
cc0cc71832660334c669df34ca8e632f101f878fdf5767dd31be07e0e92026ce
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top